Stocks · News reference

Corcept Reports Favorable Survival and Response Data in Ovarian Cancer Study

Oct 26, 2026, 4:25 PMVandana Singh

Corcept Therapeutics reported positive Phase 2 BELLA trial data for Lifyorli and chemotherapy in platinum-resistant ovarian cancer patients.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Fiscal.aiOct 26, 2026, 6:02 PM
Corcept Therapeutics Announces Positive Phase 2 BELLA Trial Results for Lifyorli Combination in Ovarian Cancer
Corcept Therapeutics reported positive results from its Phase 2 BELLA trial, showing that the combination of Lifyorli with nab-paclitaxel and bevacizumab slowed disease progression in patients with platinum-resistant ovarian cancer.
CORT
BenzingaOct 20, 2026, 8:02 PMBenzinga Newsdesk
Corcept Therapeutics Says ADA And EASD Recommend Hypercortisolism Screening In Difficult-To-Control Type 2 Diabetes, Citing Its CATALYST Mifepristone Trial
CORT
Zacks Investment ResearchOct 2, 2026, 10:57 AMNa
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.
ABT CORT PGEN BHC